June 7, 2019

June 07, 2019

FCC gives phone companies new tools to fight robocalls

WLOX- June 6

Federal regulators voted Thursday to give phone companies the right to block unwanted calls without getting customers' permission first. A hospital in Florida, the Moffitt Cancer Center, received 6,600 calls over 90 days faked to look as though they were coming from inside the hospital, diverting 65 hours of staff time from patient care.

 

More help to fight robocalls? Regulators to vote Thursday

Associated Press – June 6

New technology should help fight the problem, but the government must force carriers to implement it, said Dave Summitt, Moffitt's cybersecurity executive.

"We can't do it by ourselves," he said. "We need help."

 

Moffitt Cancer Center tracked nuisance calls

Bay News 9 – June 6

Moffitt Cancer Center chief security officer has been tracking this and said Moffitt received 6,600 nuisance calls over 90 days.

 

Florida man opts for rare, drastic surgery to prevent pancreatic cancer

WTSP – June 5

Doug Janousek will alter the course of his life with a rare, drastic preventative surgery at Moffitt Cancer Center.

 

FCC fighting robocalls

Altoona Mirror – June 5

A hospital in Florida, the Moffitt Cancer Center, received 6,600 calls over 90 days faked to look as though they were coming from inside the hospital, diverting 65 hours of staff time from patient care.

 

4 Israeli space-tech firms win innovation grants

Isreal 21 c – June 5

SpacePharma (Herzliya, Israel) and CadW Therapeutics/Moffitt Cancer Center (Tampa, Florida), which are developing a microfluidics Lab-On-A-Chip that analyzes stress and DNA damage/responses during space flight.

 

Clinical Challenges: Incorporating CDK4/6 Inhibitors Into Breast Cancer Care

MedPage Today – June 5

Said Heather Sook Han, MD, research director in the Department of Breast Oncology at Moffitt Cancer Center in Tampa, Florida: "You can't really say that one medication is better than the other because of the efficacy data. The main difference between them at this point is in terms of toxicity. And that may be how we consider using these medications on certain patients."

 

Amgen’s bispecific antibody AMG 420 shows high response rate in multiple myeloma at ASCO

Medcity News – June 3

The leukemia expert, the Moffitt Cancer Center’s Dr. Bijal Shah, added that about 42 percent of patients in a trial of a CD19-directed CAR-T therapy for acute lymphoblastic leukemia in adults had received prior Blincyto.

 

The Best Cancer Hospital in Every State

Reader’s Digest – June 3

Besides providing excellent treatment, the focus at the Moffitt Cancer Center is supporting both the patients and their families and loved ones. 

 

Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

BusinessWire - June 3

“Anti-PD-1 therapy in oncology has been demonstrated to be a safe and effective therapeutic approach in treating certain cancers and increased lymphocyte infiltration has been associated with improved patient outcomes,” said Rohit K Jain, M.D. M.P.H., principal investigator on the Phase 1b trial and Assistant Member in Moffitt Cancer Center Department of Genitourinary Oncology. 

 

Novi film producer interviews local residents affected by cancer in new documentary

Oakland Press – June 3

Other participating institutions include C.S. Mott Children's Hospital, Children's Hospital of Michigan, Moffitt Cancer Center and Boca Raton Regional Hospital-Florida and the University.

 

Award Celebrates 40 of Oncology’s Rising Stars and Emerging Leaders Under Age 40

PR Newswire – June 3

Winners of the 2019 “40 Under 40 in Cancer” awards were selected by a panel of judges and include the following: Stephen Rosenberg, MD, Moffitt Cancer Center

 

Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting

Globe Newswire – June 3

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pepinemab in combination with avelumab in non-small cell lung cancer (NSCLC) subjects were reported during a poster session on Saturday, June 1 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Michael Shafique, M.D., Assistant Professor of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and first author of the presentation, presented “Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC” during the Developmental Immunotherapy and Tumor Immunobiology poster session.

 

Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Globe Newswire – June 3

“These new data for 5F9 show encouraging clinical activity in a broad population of patients with MDS and AML, who may be unfit for existing therapeutic options or at higher risk for developing rapidly-advancing disease,” said David Sallman, M.D., H. Lee Moffit Cancer Center and Research Institute, an investigator for the clinical trial.

 

Korea expanding presence in global oncology field

Korea Biomedical Review – June 3

Professor Eric B. Haura from the department of thoracic oncology at the Moffitt Cancer Center and Research Institute in the U.S. also caught the eyes of participants with a bispecific JNJ-372 as a way to overcome resistance for Osimertinib.

 

Survivors of cancer share hopeful messages

Villages Daily Sun – June 2

Dr. Bryan McIver, deputy physician-in-chief at Moffitt Cancer Center, credits shifting thinking in late-stage care with rising late-stage survivorship.

 

Tumor-infiltrating lymphocyte therapy appears safe, effective in melanoma, cervical cancer

Healio – June 2

“Taking the tumor out of the patient allows us to grow these lymphocytes to a far greater number,” Amod Sarnaik, MD, surgical oncologist with the Melanoma Center of Excellence at Moffitt Cancer Center and lead author of the LN-144 study, told HemOnc Today.

 

IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer

BusinessWire – June 2

Jhanelle Gray, MD, Director of Clinical Research in the Thoracic Oncology Department at Moffitt Cancer Center in Tampa, Florida, and an investigator in the PACIFIC trial, said: “In the past, patients with unresectable, Stage III non-small cell lung cancer faced five-year survival rates of only 15 to 30%. 

 

Gilead’s ZUMA-3 study shows continued efficacy, and results from tweaks to side effect management

MedCity News – June 1

“Going down to [1 million cells], we weren’t seeing MRD positivity, so it’s very, very encouraging,” study investigator Dr. Bijal Shah, a leukemia and lymphoma specialist at the Moffitt Cancer Center in Tampa, Florida, who presented the data, said in an interview at the ASCO meeting.

 

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

BusinessWire – June 1

“Adults with relapsed or refractory ALL represent an extremely difficult-to-treat patient population,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida.

 

AdventHealth & Moffitt Partner Up In WC!

Neighborhood News – June 1

On May 21, AHWC and the Moffitt Cancer Center officially broke ground on a new outpatient center to serve cancer patients as part of a new medical office building on the AHWC campus.

 

New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer

OncLive – June 1

JNJ-61186372 elicited a response rate in 30% of 108 participants with diverse primary and secondary EGFR mutations who received the therapy in doses ranging from 700 mg to 1400 mg, said Haura, a senior member in the Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute

 

What is benign breast disease?

US News and World Report – May 31

Women need to understand that not every palpable lump in the breast is an issue. However, it’s important when they notice anything to seek an evaluation by a health care provider who can discern the difference,” says Dr. Susan Hoover, surgical oncologist specializing in breast cancer at the Moffitt Cancer Center Department of Breast Oncology.

 

Port St. Lucie woman will tackle Mount Washington to raise money for multiple myeloma research

TC Palm – May 31

“We saw a specialist in Gainesville, went to Moffitt (Cancer Center) in Tampa, and by the time it was diagnosed, it was very advanced,” said Arango, 60.

 

Gasparilla Island Kids Classic Tarpon Tournament this weekend

Boca Beacon – May 31

With great support from their sponsors and contributors, and in just eight short years, Boca Grande Charities, Inc. has now raised more than $225,000 for institutions and programs such as Moffitt Cancer Center, All Children’s Hospital, The Englewood Community Care Clinic, The Island School, Lemon Bay Conservancy, the Charlotte County School System’s S.T.E.M Camp program, EasterSeals of Southwest Florida and the Dee Wheeler Scholarship Fund.

 

Komrokji Reviews the Advantages of JAK2 Inhibitors in a Case Study of a Patient With Myelofibrosis

Targeted Oncology – May 24

In addition, Komrokji, a senior member of the Malignant Hematology and Experimental Therapeutics Program and head of the Leukemia and Myelodysplastic Syndrome Section and vice chair of the Malignant Hematology Department at the Moffitt Cancer Center, discussed treatment options based on the case scenario of a patient with myelofibrosis (MF).

 

The Handoff: Transferring CAR T Patients Back to the Community Setting

Healio – May 24

In this installment of In Practice, Julio C. Chavez, MD, assistant member in the lymphoma section of the department of malignant hematology at Moffitt Cancer Center, will discuss the challenges and best practices when preparing patients and their community oncologist for departure from the cell therapy clinic and back to the community setting.

 

‘I was a 31-year-old kid in a way’: How a cancer diagnosis changed a health care reporter

STAT – May 24

A longtime lobbyist in Tallahassee, who I don’t even know but who follows me on Twitter — I tweet often about cancer and also health care topics that I’m writing about — he knew the founder of Moffitt Cancer Center, H. Lee Moffitt, and called him.

 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.